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The amino acid sequence of human factor D is proposed from the analysis of the peptides produced by 
treatment of the factor D with cyanogen bromide, iodosobenzoic acid, trypsin and V-8 protease. 
Comparison of the proposed sequence with the sequences of other serine esterases indicated that factor 
D, although it is a plasma serine esterase, is more closely related to certain proteases not found in the 
plasma than to other plasma serine esterases of the complement system. For example, 36% and 32% 
identity in amino acid sequence was found on comparison of factor D with elastase and group-specific 
protease, respectively. Whereas only 27% and 18e70 identity was observed between factor D and the other 
complement serine esterases, Clr and factor B, respectively. 
Human factor D Sequence 
1. INTRODUCTION 
Factor D, of the alternative pathway of human 
complement, has been shown to be a typical serine 
protease both by its irreversible inhibition by di- 
isopropyl phosphorofluoridate [1] and by amino 
acid sequence analysis of the N-terminal, and ac- 
tive site, regions of the molecule [2-41. The N- 
terminal amino acid sequence of factor D is more 
similar to that of rat group-specific protease [S] 
and porcine elastase [6] than to some of the serine 
esterases of the complement and clotting systems 
[3]. In this respect it is of interest that like rat 
group-specific protease, there is no strong evidence 
for the existence of a zymogen form of the enzyme. 
The physiological role of factor D is as an activator 
of the complex protease C3b, I3 which is a Mg2+ 
dependent complex of factor B and activated 
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Esterase Homology 
C3[7]. The splitting of a single Arg-Lys polypep- 
tide bond in the factor B results in the formation 
of an active enzyme C3b,Bb which can split intact 
C3 the central component of the alternative, and 
classical, pathways of complement. 
2. MATERIALS AND METHODS 
2.1. Isolation of human factor D 
Human factor D was isolated from outdated 
plasma by a procedure [8] involving euglobulin 
precipitation, ion-exchange chromatography on 
CM-Sephadex C-50 and CM-cellulose-32, gel- 
filtration on Sephadex G-75, and affinity 
chromatography. 
2.2. Preparation and isolation of peptides used 
in the sequencing studies 
The cyanogen bromide (CNBr)-derived peptides 
were prepared and purified as in 131. Treatment of 
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factor D with iodosobenzoic acid (IBA) was per- 
formed as follows: reduced and alkylated factor 
D(lOO nmol) and IBA (1 mg) were dissolved in 1 .O 
ml of a 38.2% (w/v) guanidine hydrochloride in 
80% (v/v) acetic acid, the mixture was incubated 
in a sealed flask, in the dark, for 24 h at 25°C [9] 
then applied to a column (1.5 cm x 100 cm) of 
Sephadex G-50 superfine equilibrated with 5% 
(v/v) formic acid. The large IBA-peptides were 
further purified on Sephadex G-75 superfine 
equilibrated with 10% (v/v) formic acid and the 
low i&f, peptides were desalted on Sephadex G-10 
equilibrated with 0.1 M NH~HCOJ. 
2.3. Amino acid analysis and sequence 
determination 
Amino acid analysis was carried out as in [12]. 
Automated amino acid sequence determination 
was performed on a Beckmann 890C Sequencer 
and the phenylthiolhydantoin derivatives were 
identified and quantitated by HPLC [12]. 
3. RESULTS AND DISCUSSION 
It can be seen (table 1) that the number of 
residues calculated by amino acid analysis, for fac- 
2.3. Trypsin treatment of factor D Table 1 
Succinylated, reduced and alkylated, factor D 
(90 nmol) in 1.45 ml of 0.1 M NHdHCO3 (pH 8.0) 
was digested with TPCK-treated trypsin (4Opg) at 
37°C for 4 h. The digest was stopped by the addi- 
tion of di-isopropyl phosphorofluoridate (30-fold 
excess over the trypsin present). The digest was 
spun at 45 000 x g for 20 min and the supernatant 
applied to a column (1.5 cm x 100 cm) of 
Sephadex G-75 superfine equilibrated with 0.1 M 
NH4HCOj. The major peptides were further 
purified by HPLC on a p-Bondapak C- 18 column 
(0.39 cm x 30 cm) equilibrated with 0.1% (w/v) 
NHdHCO3 containing 5% (v/v) CHXN. The pep- 
tides were eluted over a period of 1 h in a linear 
gradient from 5% to 65% (v/v) CHXN in 0.1% 
(w/v) NHdHCOj at a rate of 1.0 ml/min. 
Amino acid compositions of factor D and its cyanogen 
bromide-derived peptides” 
Amino 
acid 
Factor D 
Residues/m01 
CNBr-1 CNBr-2 CNBr-3 
2.4. Cleavage by V-8 protease 
Peptide CNBr-1 (100 nmol) was digested with 
V-8 protease from S. aureus (0.08 mg) in 1.2 ml of 
0.1 M NH4HCOs [lo] for 8 h at 37°C. The digest 
was freeze-dried then the peptides were purified by 
HPLC, as described above, except that a gradient 
from 5% to 55qo (v/v) CHXN in 0.1% (w/v) 
NHdHCOs was used. 
'hCysb 
ASX’ 
Thr 
Ser 
Glx’ 
Pro 
Gly 
Ala 
Val 
Metd 
Ile 
Leu 
Tyr 
Phe 
His 
LYs 
Arg 
Trp’ 
X 
8.4 (8) 
18.6 (18) 
8.2 (7) 
14.4 (12) 
18.6 (16) 
14.4 (13) 
21.7 (23) 
21.7 (22) 
20.0 (23) 
2.2 (2) 
5.2 (5) 
23.7 (28) 
4.1 (4) 
1.4 (1) 
8.2 (6) 
7.2 (7) 
16.5 (17) 
3.4 (4) 
- (2) 
4.2 (4) 
12.6 (13) 
5.2 (5) 
6.3 (6) 
12.9 (12) 
9.5 (10) 
9.5 (12) 
12.6 (15) 
13.3 (16) 
0.9 (1) 
3.1 (2) 
21.7 (24) 
1.0 (1) 
1.2 (1) 
6.9 (5) 
4.2 (4) 
10.3 (10) 
NE (3) 
- (2) 
(218) (146) (57) (15) 
2.5. Digestion with carboxypeptidase Y 
The method in [l l] was used: protein, or pep- 
tide (5 nmol), and carboxypeptidase Y (5-lO/rg) in 
acetic acid-pyridine (100,~1, pH 5.5) was incubated 
at 25°C for times between 0 and 5 h. The samples 
were boiled for 5 min to stop enzyme action and 
freeze-dried prior to amino acid analysis. 
‘Comparison of values from acid hydrolysates with 
those obtained by sequence analysis. The figures in 
brackets indicate the results of sequence analysis 
“/2Cys was determined as S-carboxymethylcysteine 
‘ASX = 14 Asp + 4 Asn; Glx = 10 Glu + 6 Gln 
dMet was determined as methionine in factor D and as 
homoserine in the CNBr-derived peptides 
‘Trp was determined after hydrolysis of factor D in 4 N 
methanesulphonic acid 
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4.0 (4) 0.1 (0) 
5.2 (5) 0.3 (0) 
2.1 (2) 0.1 (0) 
5.6 (6) 0.1 (0) 
2.6 (2) 2.1 (2) 
2.6 (2) 1.1 (1) 
7.4 (9) 2.2 (2) 
4.8 (4) 2.7 (3) 
5.8 (7) 0.3 (0) 
0.2 (0) 0.7 (1) 
2.1 (2) 0.8 (1) 
2.8 (3) 1.0 (1) 
1.7 (2) 0.9 (1) 
0.4 (0) - (0) 
0.4 (0) 1.0 (1) 
3.3 (3) - (0) 
5.4 (5) 1.6 (2) 
NE (1) - (0) 
- (0) - (0) 
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tor D and its CNBr-peptides, agrees closely with 
those predicted from the amino acid sequence 
analysis (table 1; fig. 1). This indicates that, despite 
the lack of ‘overlap’ peptides in certain positions 
(fig.l), no large stretch of amino acid sequence 
could have been omitted from the proposed se- 
quence. From the amino acid composition data the 
only region where it is considered possible that 
there may be residues not accounted for is in the 
region 68-69 where the insertion of 2, or 3 residues 
cannot be excluded at present. However, the se- 
quence presented in fig. 1 should allow for the 
preparation of suitable oligonucleotide probes 
which could be used to screen cDNA libraries for 
the provision of the cDNA sequence which would 
then allow the confirmation, or correction, of the 
proposed amino acid sequence. 
Virtually all the residues which are invariant in 
other serine proteases are also found in equivalent 
positions in factor D. An exception is residue 184 
(the chymotrypsinogen numbering is used 
throughout the Discussion) which is usually Gly 
1 10 20 30 
ILGGREAEAHARPYMASVQLNGAELCGGVLVA 
I CNBr-3 1. CNBr-1 
: T7b;II 
IBA-f 
1 
. T-7b-1 T-3 
4 
E Q W V L T A i(H)C 
5 
L E D A A G G :: V(R)V L L G A(SjT? S Q P E 
CNBr-1 
IBA-1 ,, IBA-2 
I-J 
/O 80 
I 
90 
(F)X K(R)E V L R A V P H P D S Q P D T IDHDLLLLQLSEK 
CNBr-1 
7"" n 
t T-5a 
& V8-8 
110 
t 
100 120 
ATLGPAVXPLPWGRVDRDVAPGTLCDVAGWGI 
CNBr-1 
IBA-2 IBA-3 
T-5a T 6 II 
IJA_4 
130 140 150 - 160 
VNHAGRRPDSLQHVLLPVLDRAKCRLYDVLRL 
CNBr-1 
IBA-4 
T-6-11 T-6-111 4 1 T-8 (C 
161 170 180 190 
MCAESNRRDSCKGDSGGPLVCGGVLEGVVTSG 
-_(I CNBr=2 
IBA-4 
S(R)VCGNRKKPGIYTRVASYAAWIDVL 
CNBr-7 cc I 
IBA 4 
T_5b,) T-6 .-. 
IBA-5 , 
T-7a-I . T-7a-II I 
Fig. 1. Proposed amino acid sequence of human factor D. Peptides prefixed by CNBr-, IBA-, T- and V8- were derived 
from cyanogen bromide, idosobenzoic acid, trypsin and VS-protease digests respectively. The N-terminal sequences of 
the 3 CNBr-derived peptides have been published in [3]. Extensive N-terminal sequence analysis was performed on all 
the peptides shown and positive identifications of residues were obtained at all positions except where the residue is 
enclosed in brackets, denoting tentative identification, or given as X, denoting an unidentified residue. Sequence deter- 
mination from the C-terminus by use of carboxypeptidase Y is shown by +. No overlap in amino acid sequence was 
obtained at positions 69, 108, 149, 153, 159, 194, 199 and 207. 
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ELASTASE PIG: 
Fig. 2. Comparison of the amino acid sequence of factor D with the sequences of group-specific protease and elastase. 
The rat GSP and pig elastase amino acid sequences are taken from [S] and [6], respectively. Residues common to GSP 
and factor D, or elastase and factor D, are boxed. X denotes an unidentified residue; - denotes gap introduced to max- 
imise homology. 
but in factor D is replaced by Glu. The Asp-194 
residue which forms an ion pair with Ile-16 is pre- 
sent as are the active site residues His-57, Asp-102 
and Ser-195 which form part of the charge relay 
system. Of the residues which are highly conserved 
in serine proteases many were also found in factor 
D. The specificity residue at 189 is Asp, as is ex- 
pected for an arginine-specific serine protease. An 
interesting substitution is found at residue 192 
which in other serine proteases is deeply buried in 
the zymogen form, and which, on activation, shifts 
to the surface of the enzyme and forms a flexible 
‘lid’ to the binding pocket [13]. Serine proteases 
with an Arg/Lys specificity tend to have Glu in this 
position (although factor B and thrombin are ex- 
ceptions) whereas Lys was found in factor D. 
Previously [3] the similarity of the N-terminal 20 
amino acids of factor D to the equivalent regions 
in rat group specific protease and elastase was 
noted. When similar comparisons, using the 
statistical method in [ 141 were made for the regions 
of the active site serine (chymotrypsinogen residues 
180-201), and histidine (chymotrypsinogen 
residues 42-58) the probability of a random rela- 
tionship between factor D and other sequences was 
350 
< ~0.01%. The statistic for the region of the ac- 
tive site aspartic acid (chymotrypsinogen residues 
102-112) was more variable, with the probability 
of a random relationship ranging from 0.01% 
(groups specific protease), 0.1% (elastase) to 1% 
(most other serine esterases) except for factor B 
(5%), thrombin (10%) and factor X (lo-50%). 
The apparent similarity of factor D to serine 
proteases of a non-plasma origin is further em- 
phasized by the positioning of its 8 half-cystine 
residues which appear to occur in positions 
analogous to those of elastase (fig.2). When align- 
ed with various serine esterases, factor D suprising- 
ly shows greater overall homology with group- 
specific protease and elastase giving 36% and 32% 
homology, respectively (fig.2), while comparison 
with the B chain of the complement enzyme Clr 
[15] yielded 27% homology, and comparison with 
the Bb portion of the complement enzyme factor B 
yielded only about 18% homology [ 161. 
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